Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS
NCT04359290
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
ARDS, Human
COVID
Interventions
DRUG:
Ruxolitinib administration
Sponsor
Philipps University Marburg